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It is a pleasure for us to present this special
issue of The Journal of International Medical
Research, which brings together a series of
brief communications focusing on the use of
biological therapy in rheumatology and
dermatology based on recent research into
the pathogenic mechanisms of immune-
mediated inflammatory diseases of the skin
and joints. The articles were written by
members of the faculty of a Seminar held
on 4–5 December 2014 in Sarteano, Italy
and facilitated by an unrestricted grant
from PEzer Italia. The contributors are
rheumatologists and dermatologists with
substantial experience in the treatment of
chronic inFammatory rheumatic and der-
matological conditions such as rheumatoid
arthritis, psoriasis, psoriatic arthritis, and
spondyloarthropathies.
Although the pathogenic mechanisms of
immune-mediated inflammatory diseases
are not fully understood, these apparently
unrelated conditions actually share an
immune aetiology that is mediated by cyto-
kines and immune cells. Advances in the
understanding of the inflammatory path-
ways has allowed the development of a
number of effective biological agents target-
ing specific disease mechanisms, particularly
agents that inhibit proinflammatory cyto-
kines such as tumour necrosis factor (TNF)
and interleukins. These drugs have demon-
strated their ability to control disease activ-
ity and to delay the progression of tissue
damage. However, although targeted thera-
pies provide excellent anti-inflammatory
activity in rheumatological and dermato-
logical conditions, some concerns remain
about their cardiovascular safety and poten-
tial metabolic effects. To ensure the full
therapeutic potential of any biological ther-
apy, clinicians should be aware of these
issues in order to use biological agents safely
and effectively.
This supplement covers six interesting
topics: (i) gene/molecular research on
immune-mediated diseases; (ii) immune-
mediated diseases and treatment immuno-
genicity; (iii) immune-mediated diseases and
treatment comorbidities; (iv) immune-
mediated diseases and obesity; (v) immune-
mediated diseases and cardiovascular risk;
and (vi) real-life experiences.
The first section contains papers on
recent advances in genetic and molecular
research on immune-mediated diseases.
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Among articles presented, Campanati et al.
report that the TNF-a inhibitor, etanercept,
reduces the production of the proangiogenic
cytokine vascular endothelial growth factor
(VEGF) in the mesenchymal stem cells that
are implicated in the ‘psoriatic march’– the
hypothesized cascade of events linking psor-
iasis and cardiovascular comorbidities. In a
series of articles, Chimenti et al. investigate
the action of proteins involved in inflamma-
tory pathways and their role in modulating
the immune response and inflammation.
Cacciapaglia et al. describe the effect of
TNF-a inhibition on disease activity and
levels of circulating reactive oxygen species
in patients with rheumatoid arthritis, sug-
gesting a cardioprotective role of early
treatment with TNF-a inhibitors. Ganzetti
et al. provide evidence that the expression of
interleukin 1-b in the salivary secretions of
patients with psoriasis is significantly
reduced in response to TNF-a inhibitors,
suggesting that salivary interleukin 1-b
could play a role as a noninvasive oral
inflammatory biomarker for monitoring
inflammation in psoriasis.
In the second section, Vultaggio et al.
explore the mechanisms of tolerance and
adaptive immune responses to biological
agents, pointing towards new assays that
may provide useful tools for monitoring
immunogenicity and preventing adverse
events. A paper by Potenza et al. evaluates
heart rate variability analysis as a clinical
tool to assess the influence of etanercept on
autonomic cardiovascular regulation in
psoriatic patients; while Chimenti et al.
evaluate the serum levels of the TNF-a
inhibitor adalimumab in patients with psori-
atic arthritis undergoing long-term therapy
addressing the implications of the develop-
ment of antidrug antibodies. Chimenti et al.
also investigate serological markers asso-
ciated with disease activity in patients with
rheumatoid arthritis treated with rituximab,
a genetically-engineered chimeric monoclo-
nal antibody targeted to CD20þ B cells.
The third section examines the potential
role of comorbidities in immune-mediated
diseases, encompassing papers on suicide
risk and psychiatric comorbidity by Pompili
et al.; treatment of immunocompromised
patients with psoriasis (De Simone et al.);
and the long-term safety of etanercept in
psoriasis, with particular emphasis on infec-
tions (Orsini et al.). Generali et al. analyse
data from a longitudinal study in a large
cohort of Italian subjects followed-up over a
13-year period to determine the prevalence
of antinuclear antibodies and antiextract-
able nuclear antigens and their predictive
value for the development of an auto-
immune disease.
In the fourth section, the influence of
obesity on treatment efficacy is addressed in
a study by Giunta et al., which investigated
the effect of body weight and body mass
index on the efficacy of etanercept in
patients with psoriasis.
The implications of immune-mediated
diseases on cardiovascular risk are examined
in the fifth section, in a case–control study
from Erre et al. investigating the role of
asymmetric dimethylarginine and arterial
stiffness in rheumatoid arthritis patients; a
review on the role of post-translational
modifications – citrullination and carbamy-
lation – in the pathogenesis of rheumatoid
arthritis and atherosclerosis, by Spinelli
et al.; and data fromMurdaca et al. showing
the beneficial effects of long-term treatment
with bosentan on endothelial dysfunction in
patients with systemic sclerosis and pulmon-
ary arterial hypertension.
The final section reports the experiences of
the contributing rheumatologists and derma-
tologists treating patients in ‘real-life’ clinical
situations. In this section, Chimenti et al.
describe the ability of anti-TNF therapy to
induce remission and reduce disease activity
in rheumatoid arthritis patients; Faleri
et al. discuss the unmet needs in patients
with psoriasis highlighting the import-
ance of multidisciplinary assessment and
4 Journal of International Medical Research 44(1S)
 at Univesita La Sapienza on November 16, 2016imr.sagepub.comDownloaded from 
management; Babino et al. report comedica-
tion patterns in patients with psoriasis treated
with etanercept; and Pezzolo et al. raise the
issue of chronic kidney disease in patients
receiving long-term therapy for psoriasis. De
Santis et al. and Conti et al. investigated the
value of nailfold videocapillaroscopy and
speckled variance optical coherence tomog-
raphy as diagnostic and monitoring tools in
immune-mediated inflammatory diseases.
The role of methotrexate as a concomitant
therapy with etanercept in patients with
rheumatoid arthritis is described in a paper
by Becciolini et al.; and Anginelli et al. report
a case of the safe and successful treatment of
scleromyxoedema with high-dose intraven-
ous immunoglobulins.
We believe that this special supplement of
The Journal of International Medical
Research highlights a range of key issues
surrounding the management of immune-
mediated inflammatory diseases that will
not only contribute towards a better under-
standing of the pathophysiology of these
complex inflammatory conditions, but will
be of practical value in informing the effect-
ive use of biological therapies in these
chronic diseases.
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